Theialife Aligned With FDA on Pediatric Myopia Program
The company reached an agreement with regulators on the design of its pivotal Phase 3 clinical trials for ND10.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you trust that new pharmaceutical treatments will solve the root causes of childhood conditions?
Theialife has completed a Type C meeting with the FDA, securing alignment on the design for its Phase 3 clinical program regarding ND10. The investigational oral therapy aims to treat progressive pediatric myopia.
Why it matters
The alignment provides a clear regulatory path for Theialife to move forward with the pivotal testing required to potentially bring a new treatment option to market for children experiencing myopia progression.
The planned program consists of two pivotal clinical trials, ORBIS 1 and ORBIS 2. Participants will receive either ND10 extended-release capsules or a placebo while wearing single-vision corrective lenses.
The players
Theialife
Theialife is a biotechnology company currently developing ND10 as an oral therapy for pediatric myopia.
FDA
The Food and Drug Administration is the federal agency responsible for regulating clinical trial designs and drug approvals in the United States.
Rupa Wong
Rupa Wong is a medical professional at the Honolulu Eye Clinic who serves as the lead for the ND10 clinical program.
The details
The upcoming Phase 3 trials will feature an interim efficacy analysis and follow-up periods to determine the durability of the ND10 treatment. Rupa Wong, based at the Honolulu Eye Clinic, will lead the clinical program as the company moves toward final study initiation.
Timeline
October 7, 2026: Theialife completed its Type C meeting with the FDA.
First half of 2027: The company aims to initiate the two pivotal clinical studies.
The Tech Race
This development follows the formal regulatory procedures established by the FDA for Type C meetings to refine study designs. By securing this alignment, the company mirrors the standard industry process for advancing specialized pediatric therapies toward late-stage clinical evaluation.
Families monitoring progressive pediatric myopia may see a new treatment option enter the research pipeline as a result of this development. The use of oral therapy could provide an alternative to current myopia management methods once clinical testing is complete.
The takeaway
The successful meeting with the FDA serves as a critical milestone in proving the viability of ND10's therapeutic approach for pediatric patients. Readers should note that while this agreement helps standardize the trial process, the path to commercial availability remains contingent on future clinical performance.
What happens next
The initiation of the two pivotal studies is tentatively scheduled for the first half of 2027, pending IND acceptance and the successful completion of Series A financing.
Further reading
For more updates on medical innovation, visit our Biotech section.
More information
For detailed company updates, visit the Theialife company information portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that new pharmaceutical treatments will solve the root causes of childhood conditions?
